Henry Schein (NASDAQ:HSIC) executives said the company is on track with its 2026 commitments and value-creation plan, while pointing to continued momentum in the U.S. dental market despite broader concerns about consumer confidence.
Speaking at a Stifel dental track event moderated by Stifel Managi
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-...
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and...
Henry Schein (NASDAQ:HSIC) executives said the company is seeing continued momentum in its dental business and remains committed to previously outlined operating improvement targets, while acknowledging softness in medical tied to a weaker respiratory illness season.
Speaking at a Bank of America h
Henry Schein’s first quarter results were well received by the market, with outperformance driven by robust gains in U.S. dental and global technology segmen...
Dental and medical products company Henry Schein (NASDAQ:HSIC) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 6.3% year...
Dental and medical products company Henry Schein (NASDAQ:HSIC) announced better-than-expected revenue in Q1 CY2026, with sales up 6.3% year on year to $3.37 ...
Dental and medical products company Henry Schein (NASDAQ:HSIC) will be reporting results this Tuesday before market open. Here’s what to expect. Henry Schein...
Looking back on dental equipment & technology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Envista (NYSE:NVST) and its...
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether t...
Over the past six months, Henry Schein has been a great trade, beating the S&P 500 by 17.3%. Its stock price has climbed to $75.99, representing a healthy 19...
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme...
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking a...
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not...
Even if a company is profitable, it doesn’t always mean it’s a great investment.
Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
